SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

S	CH	$\mathbf{E}\mathbf{I}$)IJ	LE	13	G
\sim					10	•

(AMENDMENT NO. 1)

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cytek Biosciences, Inc.

(Name of Issuer)

Common Stock (Title of Class of Securities)

> 23285D 109 (CUSIP Number)

December 31, 2023 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

⊠ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

1.	Names of Reporting Persons				
	Ming Yan				
2.	Check the Appropriate Box if a Member of a Group (see instructions)				
	(a)				
3.					
4.	Citizenship or Place of Organization				
	United States				
	5. Sole Voting Power				
Nur	Number of 6,203,867 shares (See Item 4 herein)				
Sh	Shares 6. Shared Voting Power				
	Beneficially Owned by 0				
	ch 7. Sole Dispositive Power reting				
Pe	son 6,203,867 shares (See Item 4 herein)				
V	th: 8. Shared Dispositive Power				
9.	Aggregate Amount Beneficially Owned by Each Reporting Person				
	6,203,867 shares (See Item 4 herein)				
10.	0. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)				
11.	Percent of Class Represented by Amount in Row 9				
	4.7%(1)				
12.	. Type of Reporting Person (see instructions)				
	IN				

(1) The percentage is calculated based on 130,714,906 shares of Common Stock outstanding as of December 31, 2023.

CUSIP No. 2	23285D 109	13G/A	Page 3 of 5 Page			
Item 1(a).	Name of Issuer: Cytek Biosciences, Inc., a Delaw	are corporation				
Item 1(b).	Address of Issuer's Principal Executive Offices: 47215 Lakeview Boulevard Fremont, CA 94538					
Item 2(a).	2(a). Name of Person Filing: Ming Yan					
Item 2(b).	O). Address of Principal Business Office or, if none, Residence: Cytek Biosciences, Inc. 47215 Lakeview Boulevard Fremont, CA 94538					
Item 2(c).	Citizenship: USA					
Item 2(d).	Title of Class of Securities: Common Stock					
Item 2(e).	CUSIP Number: 23285D 109					
Item 3.	If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:					
	☐ Broker or dealer registered u	under Section 15 of the Act (15 U.S.C. 780);				
	☐ Bank as defined in section 3	(a)(6) of the Act (15 U.S.C. 78c);				
	☐ Insurance company as define	ed in section 3(a)19) of the Act (15 U.S.C. 78c);				
	☐ Investment company register	red under section 8 of the Investment Company Act of 1940 (15	U.S.C. 80a-8);			
	☐ An investment adviser in acc	cordance with §240.13d-1(b)(1)(ii)(E);				
	☐ An employee benefit plan or	endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);				
	☐ A parent holding company of	r control person in accordance with §240.13d-1(b)(1)(ii)(G);				
	☐ A savings associations as def	fined in Section 3(b) of the Federal Deposit Insurance Act (12 U.	.S.C. 1813);			
	☐ A church plan that is exclude of 1940 (15 U.S.C. 80a-3);	ed from the definition of an investment company under section 3	(c)(14) of the Investment Company Ac			
	☐ A non-U.S. institution in acc	ordance with §240.13d–1(b)(1)(ii)(J);				
	☐ Group, in accordance with §					
	If filing as a non-U.S. institution	in accordance with §240.13d-1(b)(1)(ii)(J), please specify the ty	pe of institution:			
		D 2 . C.5				

Page 3 of 5 pages

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount Beneficially Owned: Includes 6,042,103 shares of Common Stock, 1,981 shares of Common Stock issuable upon the vesting of Restricted Stock Units, and 159,783 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of December 31, 2023.
- **(b)** Percent of Class: 4.7%
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: 6,203,867
 - (ii) Shared power to vote or to direct the vote: 0
 - (iii) Sole power to dispose or to direct the disposition of: 6,203,867
 - (iv) Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following \boxtimes .

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of a Group

Not applicable

Item 10. Certification

Not applicable

CUSIP No. 23285D 109 13G/A Page 5 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2024	
Date	
/s/ Ming Yan	
Signature	
Ming Yan	
Name/Title	